Orphan Drugs & Venture Capital Backed Companies
The October, 2010 issue of Life Science Leader has an interesting article entitled Orphan Drugs: Big Pharma's Next Act? The premise is that Big Pharma is turning towards orphan drug…
The October, 2010 issue of Life Science Leader has an interesting article entitled Orphan Drugs: Big Pharma's Next Act? The premise is that Big Pharma is turning towards orphan drug…
A former business development colleague of mine used to refer to some prospects as having "champagne tastes with beer wallets." His meaning was clear. It's one thing to want champagne,…
Today we learned that Lilly will close their Singapore R&D facility. This facility was focused on drug discovery in cancer and diabetes. I leave it to the powers that be…
Drug delivery is not dead! In fact, drug delivery can ba a valuable tool for developing and commercializing drugs faster and at lower cost versus NCEs.
Late last month, Johnson and Johnson (J&J) announced the results of Phase III clinical trials comparing tapentadol extended release compared to oxycodone controlled release and placebo. In this study, J&J…
Today we read the news that GSK will spin out a team of fourteen scientists and patents into a standalone company. Convergence Pharmaceuticals will focus on the development of pain…
Today we hear the news that Covance has done it again. Today they acquired two European R&D sites from Sanofi for $25 million. In addition, Sanofi agreed to purchase R&D…
Welcome to my new blog and web site! Lacerta Bio has been organized to provide a range of pharmaceutical and biotechnology business development services. Please visit our About page to…